GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

• DOI: 10.1182/blood.2018886960
• Publication Date: 2019-08-09T03:29:02Z
• Authors: Adriano Venditti; Alfonso Piciocchi; Anna Candoni; Lorella Melillo; Valeria Calafiore; Roberto Cairoli; Paolo de Fabritiis; Gabriella Storti; Prassede Salutari; Francesco Lanza; Giovanni Martinelli; Mario Luppi; Patrizio Mazza; Maria Paola Martelli; Antonio Cuneo; Francesco Albano; Francesco Fabbiano; Agostino Tafuri; Anna Chierichini; Alessia Tieghi; Nicola Stefano Fr...; Debora Capelli; Robin Foà; Caterina Alati; Edoardo La Sala; Paola Fazi; Marco Vignetti; Luca Maurillo; Francesco Buccisano; Maria Ilaria Del ...; Maria Irno-Consalvo; Tiziana Ottone; Serena Lavorgna; Maria Teresa Voso; Francesco Lo-Coco; William Arcese; Sergio Amadori
• Keywords: Myeloid; Adult; Male; Neoplasm, Residual; Adolescent; Prognosi; 610; Acute; Risk Assessment; Cytogenetics; Young Adult; 03 medical and health sciences; 0302 clinical medicine; Humans; Age Factor; Cytogenetic; Molecular Targeted Therapy; Precision Medicine; Leukemia; Adolescent; Adult; Age Factors; Combined Modality Therapy; Consolidation Chemotherapy; Cytogenetics; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm, Residual; Precision Medicine; Prognosis; Remission Induction; Risk Assessment; Young Adult; acute myeloid leukemia; young adults; Remission Induction; Age Factors; Hematopoietic Stem Cell Transplantation; Induction Chemotherapy; Middle Aged; Prognosis; Combined Modality Therapy; 3. Good health; Consolidation Chemotherapy; Settore MED/15 - MALATTIE DEL SANGUE; Leukemia, Myeloid, Acute; Residual; Neoplasm; acute myeloid leukemia Minimal Measurable Disease Risk-adapted therapy; Female; Acute Myeloid Leukemia, minimal residual disease, post-remission therapy; Human

Key PointsA risk-adapted, MRD-driven transplant strategy is a feasible approach for the treatment of younger adults with AML. Pretransplant MRD positivity should not contraindicate delivery of an allogeneic stem cell transplant.